Maryland telemedicine startup emocha reached an agreement with Dallas-based Pathway Healthcare that will bring its technology for treating opioid use disorder into a private setting for the first time.
Through emocha’s app, patients can remotely take doses of buprenorphine, used in in medication-assisted treatment for opioid use disorder.
Through emocha’s directly observed therapy, patients take their doses on video, using a smartphone’s front-facing camera.
“Emocha’s video DOT technology can improve access to medication-assisted therapy and helps patients and providers engage at critical moments during to treatment, which should lead to higher quality care and fewer overdoses,” said Sebastian Seiguer, emocha’s CEO, in a statement. “We are proud to partner with Pathway to address the opioid epidemic in the U.S. because of its commitment to providing evidence-based, compassionate care for those with substance use disorder.”
Until now, emocha’s technology had only been used in public health departments, including in Baltimore City. But the shift to a private setting could be big for the company.
Pathway is a private addiction treatment center. Most treatment for opioid use disorders take place within a private clinic or treatment center.
“Emocha’s platform will enhance patients’ treatment experiences and improve our ability to help them find the best path to recovery,” said Pathway Healthcare CEO Scott Olson, in a statement. “Patients’ daily interaction with the app gives them a direct connection to their personal Patient Care Coordinator and gives their doctor important information to tailor care plans.”